Large Molecule Clinical Bioanalysis

Clinical Bioanalysis for Complex Biotherapeutics

Large molecule clinical bioanalysis requires methods that reflect the structure, mechanism of action, exposure profile, and immunogenicity risk of the therapeutic. WuXi Biology and Testing supports global clinical studies with ligand-binding, LC-MS/MS, cell-based, and complementary bioanalytical approaches for proteins, antibodies, peptides, and other complex biologic formats.

Our teams can carry methods and critical reagents forward from preclinical development into clinical sample analysis, helping preserve assay continuity while adapting validation, sensitivity, throughput, and sample-management requirements to the clinical phase.

Clinical PK and Ligand-Binding Bioanalysis

Quantify therapeutic proteins, antibodies, and other large molecules in clinical matrices using ligand-binding assays, LC-MS/MS, or hybrid immunocapture approaches validated to the level appropriate for clinical study sample analysis. Method selection is guided by the molecule, target, matrix, expected concentration range, required sensitivity, and study objective.

Clinical PK methods can be developed, transferred, validated, cross-validated, and scaled for increasing sample volumes while maintaining consistency across study phases and laboratories.

Immunogenicity and Biomarker Support

Large molecule clinical studies often require an integrated immunogenicity strategy because anti-drug antibodies can affect exposure, pharmacology, efficacy, and the interpretation of safety. Support can include screening, confirmatory, and titer assays, as well as neutralizing antibody methods selected according to the therapeutic and mechanism.

Biomarker and pharmacodynamic assays can be aligned with PK and immunogenicity endpoints to help interpret target engagement, biological response, and clinically relevant exposure-response relationships.

Critical Reagents, Samples, and Assay Continuity

Reliable large molecule bioanalysis depends on well-characterized critical reagents and controlled sample handling. Early planning for reagent generation, qualification, supply, stability, and lifecycle management can reduce the risk of interruptions during multi-year clinical studies.

We also support sample receipt, storage, transport coordination, inventory control, method transfer, and data reporting. Coordinating these activities helps maintain sample integrity and assay comparability as clinical studies expand in size or geography.

Explore Solutions

Explore Solutions for Your Program

Explore solutions by development phase, drug modality, therapeutic area, or integrated discovery needs.

Get A Quote

Get a Quote

Ready to plan your next study? Share your program needs with our team for a tailored estimate.

Frequently Asked Questions

Get a Quote